A Randomized, Double-blind, Placebo and Active Comparator-Controlled, Parallel-Group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus

This is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled
by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. The total
duration of a subject's participation will be approximately 30 weeks, including a 2-week
placebo run-in period, a 26-week double-blind treatment period, and a 2-week post-treatment
follow-up period.